%0 Journal Article
%T Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis.
%A Clerc OF
%A Cuddy SAM
%A Jerosch-Herold M
%A Benz DC
%A Katznelson E
%A Canseco Neri J
%A Taylor A
%A Kijewski MF
%A Bianchi G
%A Ruberg FL
%A Di Carli MF
%A Liao R
%A Kwong RY
%A Falk RH
%A Dorbala S
%J JACC Cardiovasc Imaging
%V 0
%N 0
%D 2024 Jul 1
%M 39001736
%F 16.051
%R 10.1016/j.jcmg.2024.05.004
%X <B>BACKGROUND: </B>In systemic light-chain (AL) amyloidosis, cardiac involvement portends poor outcomes.<BR><B>OBJECTIVE: </B>The authors' objectives were to detect early myocardial alterations, to analyze longitudinal changes with therapy, and to predict major adverse cardiac events (MACE) in participants with AL amyloidosis using cardiac magnetic resonance imaging (MRI).<BR><B>METHODS: </B>Recently diagnosed participants were prospectively enrolled. AL amyloidosis with and without cardiomyopathy (AL-CMP, AL-non-CMP) were defined based on abnormal cardiac biomarkers and wall thickness. MRI was performed at baseline, 6 months in all participants, and 12 months in participants with AL-CMP. MACE were defined as all-cause death, heart failure hospitalization, and cardiac transplantation. Mayo stage was based on troponin T, N-terminal pro-B-type natriuretic peptide, and difference in free light chains.<BR><B>RESULTS: </B>This study included 80 participants (median age 62 years, 58% men). Extracellular volume (ECV) was abnormal (>32%) in all participants with AL-CMP and in 47% of those with AL-non-CMP. ECV tended to increase at 6 months (median +2%; AL-CMP P = 0.120; AL-non-CMP P = 0.018) and returned to baseline values at 12 months in participants with AL-CMP. Global longitudinal strain (GLS) improved at 6 months (median -0.6%; P = 0.048) and 12 months (median -1.2%; P < 0.001) in participants with AL-CMP. ECV and GLS were strongly associated with MACE (P < 0.001) and improved the prognostic value when added to Mayo stage (P ≤ 0.002). No participant with ECV ≤32% had MACE, while 74% of those with ECV >48% had MACE.<BR><B>CONCLUSIONS: </B>In patients with systemic AL amyloidosis, ECV detects subclinical myocardial alterations. With therapy, ECV tends to increase at 6 months and returns to values unchanged from baseline at 12 months, whereas GLS improves at 6 and 12 months in participants with AL-CMP. ECV and GLS offer additional prognostic performance over Mayo stage. (Molecular Imaging of Primary Amyloid Cardiomyopathy [MICA]; NCT02641145).